Apellis Pharmaceuticals, Inc. (APLS) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $40.95 (+0.01%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Nov 3, 2025 | Graig Suvannavejh | Mizuho Securities | $19.00 | -53.6% |
| Nov 6, 2024 | Douglas Tsao | H.C. Wainwright | $57.00 | +39.2% |
| Sep 23, 2024 | Colleen Kusy | Robert W. Baird | $92.00 | +124.6% |
| Sep 20, 2024 | Annabel Samimy | Stifel Nicolaus | $84.00 | +105.1% |
| Sep 20, 2024 | Graig Suvannavejh | Mizuho Securities | $39.00 | -4.8% |
| Sep 16, 2024 | Graig Suvannavejh | Mizuho Securities | $42.00 | +2.6% |
| Aug 9, 2024 | Colleen Kusy | Robert W. Baird | $96.00 | +134.4% |
| Aug 8, 2024 | Akash Tewari | Jefferies | $82.00 | +100.2% |
| Aug 2, 2024 | Douglas Tsao | H.C. Wainwright | $83.00 | +102.7% |
| Jul 26, 2024 | Colleen Kusy | Robert W. Baird | $86.00 | +110.0% |
| Jul 1, 2024 | Graig Suvannavejh | Mizuho Securities | $49.00 | +19.6% |
| May 23, 2024 | Derek Archila | Wells Fargo | $48.00 | +17.2% |
| Feb 5, 2024 | Akash Tewari | Jefferies | $80.00 | +95.3% |
| Jan 2, 2023 | Derek Archila | Wells Fargo | $58.00 | +41.6% |
| Jun 23, 2022 | Annabel Samimy | Stifel Nicolaus | $60.00 | +46.5% |
| Nov 9, 2021 | Laura Chico | Wedbush | $28.00 | -31.6% |
| Nov 9, 2021 | Matthew Luchini | BMO Capital | $69.00 | +68.5% |
| Oct 1, 2021 | Alethia Young | Cantor Fitzgerald | $74.00 | +80.7% |
| Oct 1, 2021 | Chris Howerton | Jefferies | $74.00 | +80.7% |
| Sep 10, 2021 | Tiago Fauth | Credit Suisse | $38.00 | -7.2% |
Top Analysts Covering APLS
APLS vs Sector & Market
| Metric | APLS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | — | 2.24 | 2.41 |
| Analyst Count | — | 8 | 18 |
| Target Upside | -24.3% | +1150.3% | +14.9% |
| P/E Ratio | 240.91 | 6.64 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $217M | $235M | $253M | 11 |
| 2027-03-31 | $206M | $223M | $240M | 11 |
| 2027-06-30 | $220M | $238M | $257M | 7 |
| 2027-09-30 | $233M | $252M | $271M | 8 |
| 2027-12-31 | $245M | $265M | $285M | 7 |
| 2028-03-31 | $413M | $447M | $481M | 6 |
| 2028-06-30 | $455M | $492M | $530M | 6 |
| 2028-09-30 | $485M | $525M | $565M | 11 |
| 2028-12-31 | $1.26B | $1.26B | $1.26B | 18 |
| 2029-12-31 | $1.21B | $1.36B | $1.55B | 11 |
| 2030-12-31 | $1.36B | $1.53B | $1.74B | 9 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.20 | $-0.19 | $-0.17 | 10 |
| 2027-03-31 | $-0.32 | $-0.29 | $-0.26 | 5 |
| 2027-06-30 | $-0.22 | $-0.20 | $-0.18 | 5 |
| 2027-09-30 | $-0.19 | $-0.17 | $-0.16 | 5 |
| 2027-12-31 | $-0.19 | $-0.18 | $-0.16 | 5 |
| 2028-03-31 | $1.11 | $1.23 | $1.35 | 7 |
| 2028-06-30 | $1.27 | $1.41 | $1.55 | 6 |
| 2028-09-30 | $1.38 | $1.53 | $1.68 | 6 |
| 2028-12-31 | $-0.97 | $1.21 | $8.31 | 18 |
| 2029-12-31 | $1.28 | $1.49 | $1.76 | 10 |
| 2030-12-31 | $2.10 | $2.46 | $2.89 | 8 |
Frequently Asked Questions
What is the analyst consensus for APLS?
The consensus among 0 analysts covering Apellis Pharmaceuticals, Inc. (APLS) is — with an average price target of $33.50.
What is the highest price target for APLS?
The highest price target for APLS is $96.00, set by Colleen Kusy at Robert W. Baird on 2024-08-09.
What is the lowest price target for APLS?
The lowest price target for APLS is $19.00, set by Graig Suvannavejh at Mizuho Securities on 2025-11-03.
How many analysts cover APLS?
0 analysts have issued ratings for Apellis Pharmaceuticals, Inc. in the past 12 months.
Is APLS a buy or sell right now?
Based on 0 analyst ratings, APLS has a consensus rating of — with a -24.3% upside to the consensus target of $33.50.
What are the earnings estimates for APLS?
Analysts estimate APLS will report EPS of $-0.19 for the period ending 2026-12-31, with revenue estimated at $235M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.